Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ

Diabetes

Volumn 60, Issue 9, 2011, Pages 2245-2256

  Cabou, Cendrine ^a,b   Vachoux, Christelle ^a,b   Campistron, Gérard ^a,b   Drucker, Daniel J ^c   Burcelin, Rémy ^a  

^a University Hospital of Toulouse   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; PROTEIN KINASE C DELTA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMORAL ARTERY FLOW; HORMONE ACTION; HYPERGLYCEMIA; HYPOTHALAMUS; INSULIN SENSITIVITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; FEMORAL ARTERY; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; HYPOTHALAMUS; INSULIN; MALE; MICE; MICE, KNOCKOUT; PEPTIDES; PROTEIN KINASE C-DELTA; RECEPTORS, GLUCAGON; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION; VENOMS;

EID: 80052903104     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0464     Document Type: Article

References (50)

1. Thorens B, Waeber G. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM. Diabetes 1993;42:1219-1225 (Pubitemid 23259839)
2. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996;271:E808-E813
3. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst 1996;61:149-154 (Pubitemid 26384338)
4. Knauf C, Cani PD, Kim DH, et al. Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose sensing. Diabetes 2008;57:2603-2612
5. Knauf C, Cani PD, Perrin C, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005;115:3554-3563 (Pubitemid 43121843)
6. Burcelin R, Da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001;50:1720-1728 (Pubitemid 33641588)
7. Knauf C, Cani PD, Ait-Belgnaoui A, et al. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 2008;149:4768-4777
8. Cabou C, Campistron G, Marsollier N, et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008;57:2577-2587
9. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997;77:257-270 (Pubitemid 27060323)
10. Vrang N, Hansen M, Larsen PJ, Tang-Christensen M. Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. Brain Res 2007;1149:118-126 (Pubitemid 46671416)
11. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997;138:4445-4455 (Pubitemid 27408493)
12. Navarro M, Rodriquez de Fonseca F, Alvarez E, et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996;67:1982-1991 (Pubitemid 26349672)
13. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72 (Pubitemid 26008136)
14. Cabou C, Cani PD, Campistron G, et al. Central insulin regulates heart rate and arterial blood flow: an endothelial nitric oxide synthase-dependent mechanism altered during diabetes. Diabetes 2007;56:2872-2877 (Pubitemid 350223620)
15. Suzuki Y, Zhang H, Saito N, Kojima I, Urano T, Mogami H. Glucagon-like peptide 1 activates protein kinase C through Ca2+-dependent activation of phospholipase C in insulin-secreting cells. J Biol Chem 2006;281:28499-28507 (Pubitemid 44506992)
16. McClenaghan NH, Flatt PR, Ball AJ. Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. J Endocrinol 2006;190:889-896 (Pubitemid 44560262)
17. Light PE, Bladen C, Winkfein RJ, Walsh MP, French RJ. Molecular basis of protein kinase C-induced activation of ATP-sensitive potassium channels. Proc Natl Acad Sci USA 2000;97:9058-9063 (Pubitemid 30626673)
18. Amir S, Shechter Y. Apparent involvement of protein kinase C in the central glucoregulatory action of insulin. Brain Res 1988;450:272-279
19. Ross R, Wang PY, Chari M, et al. Hypothalamic protein kinase C regulates glucose production. Diabetes 2008;57:2061-2065
20. Ramakrishnan R, Sheeladevi R, Suthanthirarajan N, Namasivayam A. An acute hyperglycemia or acidosis-induced changes of indolamines level correlates with PKC-alpha expression in rat brain. Brain Res Bull 2005;67:46-52 (Pubitemid 41225317)
21. Ramakrishnan R, Sheeladevi R, Suthanthirarajan N. PKC-alpha mediated alterations of indoleamine contents in diabetic rat brain. Brain Res Bull 2004;64:189-194 (Pubitemid 39165876)
22. Lee TS, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci USA 1989;86:5141-5145 (Pubitemid 19182249)
23. Naruse K, Rask-Madsen C, Takahara N, et al. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes 2006;55:691-698 (Pubitemid 43343225)
24. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 2002;282:E834-E842 (Pubitemid 34654745)
25. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-1772 (Pubitemid 47025442)
26. Perrin C, Knauf C, Burcelin R. Intracerebroventricular infusion of glucose, insulin, and the adenosine monophosphate-activated kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, controls muscle glycogen synthesis. Endocrinology 2004;145:4025-4033 (Pubitemid 39120547)
27. Young EA, Duchemin AM, Neff NH, Hadjiconstantinou M. Parallel modulation of striatal dopamine synthetic enzymes by second messenger pathways. Eur J Pharmacol 1998;357:15-23 (Pubitemid 28439173)
28. Redman C, Lefevre J, MacDonald ML. Inhibition of diacylglycerol kinase by the antitumor agent calphostin C. Evidence for similarity between the active site of diacylglycerol kinase and the regulatory site of protein kinase C. Biochem Pharmacol 1995;50:235-241
29. Ohsawa M, Kamei J. Modification of the expression of naloxone- precipitated withdrawal signs in morphine-dependent mice by diabetes: possible involvement of protein kinase C. Jpn J Pharmacol 1999;79:303-311 (Pubitemid 29168140)
30. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:2795-2804 (Pubitemid 37339710)
31. Borghini I, Ania-Lahuerta A, Regazzi R, et al. Alpha, beta I, beta II, delta, and epsilon protein kinase C isoforms and compound activity in the sciatic nerve of normal and diabetic rats. J Neurochem 1994;62:686-696
32. Roberts RE, McLean WG. Protein kinase C isozyme expression in sciatic nerves and spinal cords of experimentally diabetic rats. Brain Res 1997;754:147-156 (Pubitemid 27170262)
33. Irani BG, Donato J Jr, Olson DP, et al. Distribution and neurochemical characterization of protein kinase C-theta and -delta in the rodent hypothalamus. Neuroscience 2010;170:1065-1079
34. Tanaka C, Nishizuka Y. The protein kinase C family for neuronal signaling. Annu Rev Neurosci 1994;17:551-567 (Pubitemid 24117042)
35. Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev 2008;88:1341-1378
36. Azzi A, Boscoboinik D, Hensey C. The protein kinase C family. Eur J Biochem 1992;208:547-557
37. Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995;96:786-792
38. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172-1179
39. Shankar R, Zhu JS, Ladd B, Henry D, Shen HQ, Baron AD. Central nervous system nitric oxide synthase activity regulates insulin secretion and insulin action. J Clin Invest 1998;102:1403-1412 (Pubitemid 28467569)
40. Vaughan PF, Walker JH, Peers C. The regulation of neurotransmitter secretion by protein kinase C. Mol Neurobiol 1998;18:125-155 (Pubitemid 29083006)
41. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010;106:1319-1331
42. Hirata K, Kuroda R, Sakoda T, et al. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension 1995;25:180-185
43. Bredt DS, Ferris CD, Snyder SH. Nitric oxide synthase regulatory sites. Phosphorylation by cyclic AMP-dependent protein kinase, protein kinase C, and calcium/calmodulin protein kinase; identification of flavin and calmodulin binding sites. J Biol Chem 1992;267:10976-10981
44. Kim H, Sasaki T, Maeda K, Koya D, Kashiwagi A, Yasuda H. Protein kinase Cbeta selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons. Diabetes 2003;52:2102-2109 (Pubitemid 36919805)
45. Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 2000;49:684-687 (Pubitemid 30339980)
46. Vrang N, Larsen PJ, Jensen PB, et al. Upregulation of the brainstem preproglucagon system in the obese Zucker rat. Brain Res 2008;1187:116-124 (Pubitemid 350199543)
47. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008;57:2046-2054
48. Serre V, Dolci W, Schaerer E, et al. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 39,59-monophosphate levels and beta-cell glucose competence. Endocrinology 1998;139:4448-4454
49. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43-52 (Pubitemid 34743464)
50. Isacson R, Nielsen E, Dannaeus K, et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 2011;650:249-255